The cationic Ru III complexes, trans-[Ru(ma) 2 (L) 2 ]CF 3 SO 3 , where Hma = maltol = 3-hydroxy-2-methyl-4-pyrone; L = imidazole (Im) (complex 2), 1(N)-methylimidazole (N-MeIm) (3), 2-methylimidazole (2-MeIm) (4), and 4-methylimidazole (4-MeIm) (5), were synthesized via the known L = EtOH (complex 1a), and characterized by elemental analysis, 1 H NMR and IR spectroscopies, mass spectrometry, cyclic voltammetry, and (for 3 and 4) by X-ray crystallography. The trans-[Ru(ma) 2 (H 2 O) 2 ]CF 3 SO 3 complex (1b) was inadvertently isolated and characterized crystallographically, and the monomaltolato species [Ru(ma)(N-MeIm) 4 ][CF 3 SO 3 ] 2 (6) was also isolated and characterized. In vitro antiproliferatory activity of complexes 2−6 against human breast cancer cells (MDA-MB-435S) was tested using an MTT assay: 4 and 5 exhibit the lowest IC 50 values, ~5 and ~15 µmol/L, respectively, whereas cisplatin exhibits an IC 50 value of ~35 µmol/L against this cell line.
No takes yet. Share an insight, caveat, or question.
Kennedy et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: